As of 30 Sep 2025, 29 institutional investors reported holding $272,401,354 in principal (par value) of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | $0 | $0 | -$11,528 | 0 | |
| 2025 Q3 | $272,401,354 | $360,356,982 | +$10,042,576 | 112.88% | 29 |
| 2025 Q2 | $279,664,978 | $303,344,890 | +$1,783,117 | 95.39% | 26 |
| 2025 Q1 | $277,011,293 | $276,983,110 | +$13,928,963 | 99.8% | 28 |
| 2024 Q4 | $264,062,863 | $250,352,690 | +$9,068,361 | 95.24% | 21 |
| 2024 Q3 | $257,683,037 | $224,077,029 | +$11,646,891 | 86.4% | 25 |
| 2024 Q2 | $253,865,742 | $203,588,240 | -$12,098,644 | 64.79% | 18 |
| 2024 Q1 | $273,167,017 | $213,304,940 | -$34,118,990,829 | 63.47% | 18 |
| 2023 Q4 | $334,700,000 | $220,380,890 | +$19,486,212 | 66.0% | 20 |
| 2023 Q3 | $294,103,687 | $220,736,211 | -$7,122,895 | 64.74% | 23 |
| 2023 Q2 | $302,695,661 | $268,074,617 | -$150,525 | 81.11% | 22 |
| 2023 Q1 | $313,618,710 | $339,699,257 | +$7,322,635 | 98.3% | 22 |
| 2022 Q4 | $301,789,743 | $296,641,638 | -$17,002,090 | 91.21% | 24 |
| 2022 Q3 | $278,749,358 | $290,720,538 | -$118,703 | 102.0% | 23 |
| 2022 Q2 | $284,858,632 | $696,807,834 | -$20,385,525 | 100.32% | 25 |
| 2022 Q1 | $302,278,349 | $747,951,345 | +$747,952,452 | 106.45% | 25 |